Vinge advises EQT in connection with the acquisition of leading global pest control specialist Anticimex which becomes the first investment of EQT’s new purpose-driven strategy with longer-term investments and impact at its core.

Anticimex is a modern service company working with pest control, food safety, damp control, house inspections and fire protection. Anticimex has since 1934 developed from being a Swedish family business to an international company with over 4,500 employees in 17 countries. The transaction, where the selling party is the EQT VI fund, has an enterprise value of SEK 60 billion and the investment is made together with several long-term investors, such as Melker Schörling AB (MSAB), who will be the second largest shareholder, GIC, AMF, Interogo Holding Long-Term Equity and Alecta.

Vinge’s team consists of Christina Kokko and Peter Sundgren together with Maria Dahlin Kolvik, Ellinor Wargenbrant, Manne Bergström and Nando Basic (M&A/Corporate), Louise Brorsson Salomon, Seyran Sahin, Karl-Gustaw Tobola and Axel Jansson (Banking and Finance), Viveka Classon, Paulina Malmberg and David Lundahl (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén and Elias Bohlin (Financial Services), Sofia Bergenstråhle (IPR), Isabell Nielsen (Commercial Agreements), Elin Broman (Employment), Lina Österberg and Ulf Pyk (Real Estate and Environment), Mika Jordan (IT), Nicklas Thorgerzon (GDPR) and Jessica Öijer (VDR). Partner Marcus Glader together with Emma Johansson and Johan Wahlbom advice in relation to merger filing.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025